The IVO-LUNG Study
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSun Yat-sen University
About this trial
This Phase II, open-label, single-arm study evaluates the efficacy and safety of one-year Ivonescimab consolidation therapy in patients with unresectable Stage III NSCLC who have not progressed after definitive chemoradiotherapy.
Eligibility criteria
Qualifiers
Provide voluntary written informed consent.
age: 18-75 years old
ECOG performance status: 0 or 1
With a life expectancy of ≥ 3 months.
Disqualifiers
Patients with non-small cell lung cancer (NSCLC) that contains a small cell carcinoma component.
History of other malignancies (except carcinoma in situ of the cervix, non-melanoma skin cancer, bladder carcinoma in situ, etc.) or presence of other life-threatening diseases that may affect the completion of the study.
Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study.
Imaging during the screening period shows tumor invasion or the presence of significant necrosis or cavitation, and the investigator judges that study entry would pose a bleeding risk.
Trial design
Treatments tested in this trial
- Ivonescimab
Treatment groups
63 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov